![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan (H.H., M.T., H.J.S., E.B., P.J., S.K., M.A., N.A., H.E.); Department of Clinical Preventive Medicine, Nagoya University School of Medicine, Nagoya, Japan (K.T., A.E., T.N.); Department of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan (M.L.O., A.T.); and Kobuchizawa Laboratories, Fuji Biomedixs Co., Yamanashi, Japan (S.N., X.-L.H.)
Received August 26, 2003; accepted November 5, 2003.
| Abstract |
|---|
|
|
|---|
|
Carbonic anhydrase plays an important role in bicarbonate reabsorption from the proximal tubule (Ives, 2001
). Acetazolamide, a major carbonic anhydrase inhibitor, blocks the re-absorption of sodium bicarbonate, resulting in an alkaline diuresis with loss of sodium and bicarbonate in the urine. Tubular secretion of acetazolamide was demonstrated to be important for the elimination of this drug in the study using the isolated rat perfused kidney (Taft and Sweeney, 1995
).
The secretion of numerous organic anions, including endogenous metabolites, drugs, and xenobiotics, is an important physiological function of the renal proximal tubule. The process of secreting organic anions through the proximal tubule cells is achieved via unidirectional transcellular transport involving the uptake of organic anions into the cells from the blood across the basolateral membrane, followed by extrusion across the brush-border membrane into the proximal tubule fluid. Recently, cDNAs encoding the human organic anion transporter (hOAT) family have been successively cloned, including hOAT1 (Reid et al., 1998
; Hosoyamada et al., 1999
), hOAT2 (Enomoto et al., 2002
), hOAT3 (Cha et al., 2001
), and hOAT4 (Cha et al., 2000
). As shown Fig. 1, hOAT1, hOAT2, and hOAT3 have been shown to be localized to the basolateral side of the proximal tubule (Hosoyamada et al., 1999
; Cha et al., 2001
; Enomoto et al., 2002
; Motohashi et al., 2002
), whereas hOAT4 is localized to the apical side of the proximal tubule (Babu et al., 2002a
).
|
Although Uwai et al. (2000
) have already demonstrated the interactions of rat OAT1 (rOAT1) with diuretics using an oocyte expression system, the molecular mechanisms underlying the renal handling of diuretics have been poorly clarified. Thus, the purpose of this study was to elucidate the interactions of hOATs with diuretics using the second segment of the proximal tubule (S2) cells stably expressing hOAT1, hOAT2, hOAT3, and hOAT4 (S2 hOAT1, S2 hOAT2, S2 hOAT3, and S2 hOAT4). Diuretics tested in the current study are listed in Table 1.
| Materials and Methods |
|---|
|
|
|---|
(PGF2
) (6808 GBq/mmol), and [3H]estrone sulfate (ES) (1961 GBq/mmol) were purchased from PerkinElmer Life Sciences (Boston, MA). [3H]Bumetanide (185.6 GBq/mmol) was purchased from Muromachi Chemicals (Tokyo, Japan). Diuretics were obtained from Sigma-Aldrich (St. Louis, MO). Other materials used included fetal bovine serum, trypsin, and geneticin from Invitrogen (Carlsbad, CA); recombinant epidermal growth factor from Wakunaga (Hiroshima, Japan); insulin from Shimizu (Shizuoka, Japan); RITC 80-7 culture medium from Iwaki Co. (Tokyo, Japan); and TfX-50 from Promega (Madison, WI).
Cell Culture. S2 cells were established by culturing the microdissected S2 segment derived from transgenic mice harboring the temperature-sensitive simian virus 40 large T-antigen gene. The establishment and characterization of S2 hOAT1, S2 hOAT2, S2 hOAT3, and S2 hOAT4 were reported previously (Takeda et al., 2002a
,b
). Briefly, the full-length cDNAs of hOAT1, hOAT2, hOAT3, and hOAT4 were subcloned into pcDNA 3.1 (Invitrogen), a mammalian expression vector. S2 hOAT1, S2 hOAT2, S2 hOAT3, and S2 hOAT4 were obtained by transfecting S2 cells with pcDNA3.1-hOAT1, pcDNA3.1-hOAT2, pcDNA3.1-hOAT3, and pcDNA3.1-hOAT4, using TfX-50 according to the manufacturer's instructions. S2 cells transfected with pcDNA3.1 lacking an insert were designated as S2 pcDNA 3.1 (mock) and used as control. These cells were grown in a humidified incubator at 33°C and under 5% CO2 using RITC 80-7 medium containing 5% fetal bovine serum, 10 µg/ml transferrin, 0.08 U/ml insulin, 10 ng/ml recombinant epidermal growth factor, and 400 µg/ml geneticin. The cells were subcultured in a medium containing 0.05% trypsin-EDTA solution (containing 137 mM NaCl, 5.4 mM KCl, 5.5 mM glucose, 4 mM NaHCO3, 0.5 mM EDTA, and 5 mM Hepes; pH 7.2) and used for
25 to 35 passages. Clonal cells were isolated using a cloning cylinder and screened by determining the optimal substrate for each transporter, i.e., [14C]PAH for hOAT1 (Hosoyamada et al., 1999
), [3H]PGF2
for hOAT2 (Enomoto et al., 2002
), and [3H]ES for hOAT3 and hOAT4 (Cha et al., 2000
, 2001
).
Uptake Experiments. Uptake experiments were performed as described previously (Takeda et al., 2002a
,b
). The S2 cells were seeded in 24-well tissue culture plates at a density of 1 x 105 cells/well. After the cells were cultured for 2 days, the cells were washed three times with Dulbecco's modified phosphate-buffered saline solution (DPBS) (containing 137 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, 1 mM KH2PO4, 1 mM CaCl2, and 0.5 mM MgCl2; pH 7.4) and then preincubated in the same solution in a water bath at 37°C for 10 min. The cells were then incubated in a solution containing various substrates at 37°C for 30 min. The uptake was stopped by the addition of ice-cold DPBS, and the cells were washed three times with DPBS. The cells in each well were lysed with 0.5 ml of 0.1 N sodium hydroxide and 2.5 ml of aquasol-2, and radioactivity was determined using a
-scintillation counter (LSC-3100; Aloka, Tokyo, Japan).
Inhibition Study. To evaluate the inhibitory effects of diuretics on organic anion uptake mediated by hOAT1, hOAT2, hOAT3, and hOAT4, the cells were incubated in a solution containing either [14C]PAH for 2 min (hOAT1), [3H]PGF2
for 20 s (hOAT2), or [3H]ES for 2 min (hOAT3 and hOAT4) in the absence or presence of various concentrations of diuretics at 37°C. Each hOAT mediates the transport of each substrate with a high affinity, which is consistent with the original reports (Hosoyamada et al., 1999
; Cha et al., 2000
, 2001
; Enomoto et al., 2002
). The Km value of hOAT1 for PAH is 20. 1 µM, that of hOAT2 for PGF2
is 425 nM, that of hOAT3 for ES is 2.2 µM, and that of hOAT4 for ES is 9.9 µM. Diuretics were dissolved in dimethyl sulfoxide and diluted with the incubation medium. The final concentration of dimethyl sulfoxide in the incubation medium was adjusted to less than 0.2%. We have chosen the incubation time for the inhibition experiment based on the following reasons. One is that the uptake of the standard substrate by each hOAT increased linearly. Another is that the uptake of the standard substrate by each hOAT was much higher than that by mock, as described in previous reports (Enomoto et al., 2002
; Takeda et al., 2002a
). The uptake by hOAT1, hOAT2, hOAT3, and hOAT4 were approximately 16-, 26-, 37-, and 31-fold higher than that by mock, respectively. Thus, even if diuretics exerted any inhibitory effects on organic anion uptake by mock, it would be negligible. Based on these results, we have not performed the inhibition experiments on mock.
Kinetic Analysis of Inhibition. After preincubation as described above, S2 hOAT1, S2 hOAT2, S2 hOAT3, and S2 hOAT4 were incubated in a solution containing [14C]PAH (hOAT1), [3H]PGF2
(hOAT2), and [3H]ES (hOAT3 and hOAT4) at various concentrations in the absence or presence of diuretics at 37°C either for 2 min (hOAT1, hOAT3, and hOAT4) or 20 s (hOAT2). The concentrations of diuretics used were as follows: 100 µM hydrochrolothiazide, 20 µM bumetanide, 50 µM furosemide, and 150 µM acetazolamide for hOAT1; 2000 µM hydrochlorothiazide, 300 µM bumetanide, and 1000 µM furosemide for hOAT2; 2000 µM hydrochrolothiazide, 5 µM bumetanide, 25 µM furosemide, and 1500 µM acetazolamide for hOAT3; and 750 µM bumetanide, 100 µM furosemide, and 1000 µM acetazolamide for hOAT4. Analyses of Lineweaver-Burk plots were performed as described previously by us (Babu et al., 2002a
).
High-Performance Liquid Chromatography (HPLC) Analysis of Furosemide. After preincubation as described above, S2 hOAT1, S2 hOAT2, S2 hOAT3, S2 hOAT4, and mock were incubated in a solution containing 500 µM furosemide at 37°C for 2 min. After washing the cells with DPBS, the cells were extracted with 0.1 N NaOH, centrifugated at 14,000 rpm for 10 min, and the supernatants were neutralized with 8 N HCl. The intracellular concentrations of furosemide were determined by HPLC as follows. High-performance liquid chromatograph was equipped with a model 880-PU pump (Jasco, Tokyo, Japan), a model 880-5 degasser (Jasco), a model 875-UV variance wavelength detector (Jasco), and a model chromatocorder 12 (SIC Co., Tokyo, Japan) under the following conditions: a reverse phase column (Develosil ODS-UG-5, 250x 4.6 mm i.d.; Nomura Chemicals Co., Aichi, Japan) with a guard column (Develosil ODS-UG-5, 10 x 4.0 mm i.d.; Nomura Chemicals Co.); mobile phase, acetonitrile/water/acetic acid (70/30/0.1) (v/v); flow rate, 1.0 ml/min; wavelength, 270 nm; and temperature, ambient temperature.
Bumetanide Efflux. The efflux study was performed as described previously (Babu et al., 2002a
,b
; Takeda et al., 2002a
). The S2 hOAT1, S2 hOAT3, S2 hOAT4, and mock were seeded in 24-well tissue culture plates at a cell density of 1 x 105cells/well. After the cells were cultured for 2 days, the cells were washed three times with DPBS and then preincubated in the same solution for 10 min in a water bath at 37°C. S2 hOAT1 exhibited the highest uptake activity compared with mock for 5-min incubation (data not shown). Thus, the monolayers were incubated at 37°C in a solution containing 300 nM [3H]bumetanide for 5 min for hOAT1 and 30 min for hOAT3 and hOAT4, washed immediately with DPBS, and incubated at 37°C in 500 µl of DPBS. After incubation for the indicated periods, 50 µl of supernatant was collected. After the incubation, the medium was aspirated immediately, and the cell monolayers were washed three times with the medium and solubilized in 0.5 ml of 0.1 N sodium hydroxide. The amount of bumetanide in the supernatant and in the cell lysate was measured. The rate of efflux at each time point was calculated using the following formula: (effluxed bumetanide by S2 hOATs - effluxed bumetanide by mock)/(bumetanide accumulated by S2 hOATs at time 0 - bumetanide accumulated by mock at time 0).
Statistical Analysis. Data are expressed as means ± S.E. Statistical differences were determined using one-way analysis of variance with Dunnett's post hoc test for the inhibition experiments and Student's t test for the uptake experiments. Differences were considered significant at P < 0.05.
| Results |
|---|
|
|
|---|
|
|
To further elucidate the inhibitory effects of diuretics on the organic anion uptake mediated by hOATs, we performed the kinetic analyses of inhibitory effects. As shown in Fig. 3, bumetanide competitively inhibited the organic anion uptake mediated by hOAT1 (A), hOAT2 (B), hOAT3 (C), and hOAT4 (D). Competitive inhibition was also seen for the inhibitory effects of hydrochlorothiazide, furosemide, and acetazolamide for hOAT1; hydrochlorothiazide and furosemide for hOAT2; hydrochlorothiazide, furosemide, and acetazolamide for hOAT3; and furosemide and acetazolamide for hOAT4 (data not shown).
|
Bumetanide Uptake Mediated by hOATs. To determine whether hOATs mediate the uptake of diuretics, we evaluated the uptake activities of [3H]bumetanide by hOATs. As shown in Fig. 4, A to C, the uptake rates of [3H]bumetanide by hOAT1, hOAT3, and hOAT4, but not by hOAT2, were higher than those by mock (*P < 0.05, **P < 0.01, and ***P < 0.001 versus control). To further elucidate the transport property of bumetanide mediated by hOAT3 and hOAT4, we performed kinetic analysis of bumetanide uptake in S2 hOAT3 and S2 hOAT4. As shown in Fig. 5, hOAT3 (A) and hOAT4 (C) mediated the dose-dependent uptake of bumetanide, and analysis of the Eadie-Hofstee revealed that the Km values for hOAT3- (B) and hOAT4 (D)-mediated bumetanide uptake were 1586 ± 69.4 nM and 306 ± 63.2 nM, respectively.
|
|
Bumetanide Efflux by hOATs. To determine whether hOAT1, hOAT3, and hOAT4 mediate the efflux of bumetanide, we measured the efflux of bumetanide from S2 hOAT1, S2 hOAT3, S2 hOAT4, and mock preincubated in a solution containing bumetanide. As shown in Fig. 6, when the efflux from mock was subtracted, S2 hOAT3 (A) and S2 hOAT4 (B) mediated the efflux of bumatnide, whereas S2 hOAT1 did not (data not shown).
|
HPLC Analysis of Furosemide. To elucidate whether hOATs mediate the uptake of furosemide, we have measured intracellular furosemide content using HPLC. As shown in Fig. 7, the uptake rates of furosemide by hOAT1 and hOAT3, but not hOAT2 and hOAT4, were higher than those by mock (n = 6, *P < 0.05 and **P < 0.01 versus mock).
|
| Discussion |
|---|
|
|
|---|
-lactam antibiotics (Hosoyamada et al., 1999
(Enomoto et al., 2002Comparing the IC50 values of diuretics among hOATs, hOAT1 exhibited the highest affinity for chlorothiazide, hydrochlorothiazide, trichlorothiazide, and acetazolamide; and hOAT3 exhibited that for bumetanide, ethacrynic acid, furosemide, and methazolamide. In contrast, hOAT2 exhibited the lowest affinity for ethacrynic acid, furosemide, and acetazolamide; hOAT4 exhibited that for cyclothiazide, hydrochlorothiazide, and bumetanide; and hOAT2 and hOAT4 exhibited that for chlorothiazide, trichlorothiazide and methazolamide. Thus, hOAT1 and hOAT3 generally exhibited higher affinity interactions with diuretics than hOAT2 and hOAT4. In addition, generally, hOAT1 seems to exhibit the highest affinity interactions with thiazides except cyclothiazide, and hOAT3 seems to do that with loop diuretics. On the other hand, it was suggested that hOAT4 exhibits higher affinity with loop diuretics than with thiazides. Furthermore, the interactions of hOATs with carbonic anhydrase inhibitors were the weakest among the diuretics tested.
HOAT3 mediated the uptake as well as efflux of bumetanide, and hOAT1 mediated the uptake of bumetanide. It is possible that the reason why hOAT1 exhibited no efflux activity of bumetanide is because it did not show as much bumetanide uptake activity as hOAT3 and hOAT4, as shown in Fig. 4. The magnitude of bumetanide uptake by hOAT3 was approximately 20-fold larger than that by hOAT1. The IC50 values of bumetanide for hOAT1 and hOAT3 in our system were similar to that of bumetanide for the basolateral PAH transport system in the isolated S2 segments of rabbit kidney proximal tubules, 3 µM (Bartel et al., 1993
). Based on these findings, it was suggested that hOAT3 mediates the uptake as well as efflux of bumetanide, and hOAT1 mediates the uptake of bumetanide in the basolateral side of the proximal tubule.
HOAT1 and hOAT3 exhibited high-affinity interactions with furosemide. In addition, hOAT1 and hOAT3 mediated the uptake of furosemide. It was reported that furosemide inhibited the basolateral PAH transport system in the isolated S2 segments of rabbit kidney proximal tubules, with an IC50 value of 40 µM (Bartel et al., 1993
). The value was similar to those of furosemide for hOAT1 and hOAT3. Bidiville and Roch-Ramel (1986
) demonstrated that probenecid inhibited the renal secretion of furosemide by 95%, whereas PAH depressed the renal secretion of furosemide by only 44 to 66% in rabbit kidneys. Based on this, Uwai et al. (2000
) hypothesized the existence of a transporter besides OAT1 that mediates the renal excretion of furosemide. Considering these lines of evidence, it was suggested that hOAT1 and hOAT3 mediate the transport of furosemide in the basolateral side of the proximal tubule.
Furosemide uptake activity by hOAT1 and the IC50 value of furosemide for hOAT1 were consistent with those of rOAT1 (Uwai et al., 2000
). However, the IC50 values of acetazolamide, bumetanide, and hydrochlorothiazide for hOAT1 were different between humans and rats (more than 3-fold difference; Zhang et al., 1998
). The reason for this may be due to the interspecies difference in the interactions of OAT1 with these drugs between humans and rats or the difference concerning the expression system, i.e., mammalian expression system for hOAT1 versus Xenopus oocyte expression system for rOAT1.
In addition to bumetanide and furosemide, because hOAT1 and hOAT3 exhibited high-affinity interactions with ethacrynic acid and thiazides, it is speculated that these transporters play important roles in the basolateral uptake of these diuretics in the proximal tubule. The IC50 value of hydrochrolothiazide for hOAT1 (67.3 µM) was comparable with that of hydrochlorothiazide for cellular PAH uptake across the basolateral membrane of isolated S2 segments in rabbits, i.e., 140 µM (Bartel et al., 1993
). In contrast, the interactions of hOAT1 and hOAT3 with carbonic anhydrase inhibitors were the weakest among the diuretics tested. However, because hOAT1 and hOAT3 seem to be a major transporters mediating the basolateral uptake of various anionic drugs (Hosoyamada et al., 1999
; Cha et al., 2001
; Khamdang et al., 2002
; Takeda et al., 2002a
,b
), it is possible that these two transporters are involved in the transport of carbonic anhydrase inhibitors. The involvement of transporters other than hOAT1 and hOAT3 in the basolateral transport of carbonic anhydrase inhibitors in the proximal tubule should also be considered. In contrast, comparing the affinities of hOATs with diuretics, hOAT2 may not significantly contribute to the transport of all the diuretics tested except cyclothiazide.
HOAT4 mediated the uptake and the efflux of bumetanide and exhibited higher affinity interactions with loop diuretics than with other diuretics. Thus, it is suggested that hOAT4 mediates the reabsorption or the efflux of loop diuretics in the apical side of the proximal tubule. In addition, considering the above-mentioned evidence that hOAT1 and hOAT3 mediate the basolateral uptake of bumetanide, it is possible that bumetanide taken up by hOAT1 and/or hOAT3 is effluxed into the urine by hOAT4, which represents the mechanism of the unidirectional transport of bumetanide. Other than the hOAT family, the interactions of other human transporters and human homologs of rodent transporters mediating organic anion transport in the apical side of the proximal tubule with diuretics should be investigated, including OAT-K1 (Saito et al., 1996
), OAT-K2 (Masuda et al., 1999
), organic anion-transporting polypeptide (oatp)1 (Jacquemin et al., 1994
), oatp2 (Noe et al., 1997
), oatp3 (Abe et al., 1998
), multidrug resistance-associated protein (MRP)2 (Leier et al., 2000
), MRP4 (van Aubel et al., 2002
), and human-type I sodium-dependent inorganic phosphate transporter (Uchino et al., 2000
). In this regard, the interaction of OAT-K1 with furosemide, as well as that of OAT-K2 with furosemide and spironolactone, was reported (Saito et al., 1996
; Masuda et al., 1999
). In addition, furosemide was shown to inhibit N-ethylmalemide glutathione uptake mediated by MRP2 (Bakos et al., 2000
).
|
The therapeutically relevant plasma concentration of a drug is considered to be within 5-fold of the maximum steady-state plasma concentration of a drug (Zhang et al.,2000
). Considering this as well as the plasma concentrations of diuretics and their unbound fractions (Hardman and Limbird, 2001
), the therapeutically relevant concentrations of unbound hydrochlorothiazide, trichloromethiazide, bumetanide, furosemide, and acetazolamide are considered to be 2.62, 0.173, 0.22, 0.41, and 33.8 µM, respectively. Thus, the IC50 values of hOAT1 for hydrochlorothiazide, trichlormethiazide, and acetazolamide are approximately 25, 100, and 2 times higher than the therapeutically relevant concentrations of unbound drugs, and those of hOAT3 for bumetanide and furosemide are approximately 3 and 18 times higher than the therapeutically relevant concentrations of unbound drugs. Thus, it is predicted that hOATs could transport these diuretics in vivo, whereas the rates of transport vary from drug to drug.
In conclusion, it was suggested that hOAT1 plays an important role in the basolateral uptake of thiazides, and hOAT3 in the uptake of loop diuretics in the proximal tubule. In addition, it was also suggested that bumetanide taken up by hOAT1 and/or hOAT3 is excreted into the urine by hOAT4, which may be the mechanism underlying the tubular secretion of bumetanide.
| Footnotes |
|---|
ABBREVIATIONS: PAH, para-aminohippuric acid; hOAT, human organic anion transporter; PGF2
, prostaglandin F2
; rOAT, rat organic anion transporter; ES, estrone sulfate; oatp, organic anion-transporting polypeptide; HPLC, high-performance liquid chromatography; MRP, multidrug resistance-associated protein; DPBS, Dulbecco's modified phosphate-buffered saline.
Address correspondence to: Dr. Hitoshi Endou, Department of Pharmacology and Toxicology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan. E-mail: endouh{at}kyorin-u.ac.jp
| References |
|---|
|
|
|---|
Abe T, Kakyo M, Sakagami H, Tokui T, Nishio T, Tanemoto M, Nomura H, Hebert SC, Matsuno S, Kondo H, et al. (1998) Molecular characterization and tissue distribution of a new organic anion transporter subtype (oatp3) that transports thyroid hormones and taurocholate and comparison with oatp2. J Biol Chem 273: 22395-22401.
Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, Cha SH, Sekine T, Sakthisekaran D, and Endou H (2002a) Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochem Biophys Acta 1590: 64-75.[Medline]
Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, and Endou H (2002b) Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol 88: 69-76.[CrossRef][Medline]
Bakhiya A, Bahn A, Burckhardt G, and Wolff N (2003) Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 13: 249-256.[CrossRef][Medline]
Bakos E, Evers R, Sinko E, Varadi A, Borst P, and Sarkadi B (2000) Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57: 760-768.
Bartel C, Wirtz C, Brandle E, and Greven J (1993) Interaction of thiazide and loop diuretics with the basolateral para-aminohippurate transport system in isolated S2 segments of rabbit kidney proximal tubules. J Pharmacol Exp Ther 266: 972-977.
Bekersky I and Popick A (1986) Disposition of bumetanide in the isolated perfused rat kidney: effects of probenecid and dose response. Am J Cardiol 57: 33A-37A.[CrossRef][Medline]
Bidiville J and Roch-Ramel F (1986) Competition of organic anions for furosemide and p-aminohippurate secretion in the rabbit. J Pharmacol Exp Ther 237: 636-643.
Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, and Endou H (2001) Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59: 1277-1286.
Cha SH, Sekine T, Kusuhara H, Yu E, Kim YJ, Kim DK, Sugiyama Y, Kanai Y, and Endou H (2000) Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 275: 4507-4512.
Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y, Yamamoto T, Sekine T, Cha SH, Niwa T, et al. (2002) Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 301: 797-802.
Gemba M, Taniguchi M, and Matsushima Y (1981) Effect of bumetanide on paminohippurate transport in renal cortical slices. J Pharmacobiodyn 4: 162-166.[Medline]
Hardman JG and Limbird LE (2001) The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill Companies, New York.
Hosoyamada M, Sekine T, Kanai Y, and Endou H (1999) Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 276: F122-F128.
Ives HE (2001) Diuretic agents, in Basic and Clinical Pharmacology, 8th ed. (Katzung BG ed) pp 245-265, McGraw-Hill Companies, New York.
Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, and Meier PJ (1994) Expression cloning of a rat liver Na+-independent organic anion transporter. Proc Natl Acad Sci USA 91: 133-137.
Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, Piyachaturawat P, and Endou H (2002) Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 303: 534-539.
Lee LJ, Cook JA, and Smith DE (1986) Renal transport kinetics of furosemide in the isolated perfused rat kidney. J Pharamacokinet Biopharm 14: 157-174.
Leier I, Hummel-Eisenbeiss J, Cui Y, and Keppler D (2000) ATP-dependent para-aminohippurate transport by apical multidrug resistance protein MRP2. Kidney Int 57: 1636-1642.[CrossRef][Medline]
Masuda S, Ibaramoto K, Takeuchi A, Takeuchi A, Saito H, Hashimoto Y, and Inui KI (1999) Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney. Mol Pharmacol 55: 743-752.
Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, and Inui K (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13: 866-874.
Noe B, Hagenbuch B, Stieger B, and Meier PJ (1997) Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 94: 10346-10350.
Odlind B and Lonnerholm G (1982) Renal tubular secretion and effects of chlorothiazide, hydrochlorothiazide and clopamide: a study in the avian kidney. Acta Pharmacol Toxicol 51: 187-197.[Medline]
Reid G, Wolff NA, Dautzenberg FM, and Burckhardt G (1998) Cloning of a human renal p-aminohippurate transporter, hROAT1. Kidney Blood Press Res 121: 233-237.
Saito H, Masuda S, and Inui KI (1996) Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J Biol Chem 271: 20719-20725.
Sweet DH, Chan LM, Walden R, Yang XP, Miller DS, and Pritchard JB (2003) Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol Renal Physiol 284: F763-F769.
Taft DR and Sweeney KR (1995) The influence of protein binding on the elimination of acetazolamide by the isolated perfused rat kidney: evidence of albumin-mediated tubular secretion. J Pharmacol Exp Ther 274: 752-760.
Takeda M, Babu E, Narikawa S, and Endou H (2002a) Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol 438: 137-142.[CrossRef][Medline]
Takeda M, Khamdang S, Narikawa S, Kobayashi Y, Yamamoto T, Kimura H, Cha SH, Sekine T, and Endou H (2002b) Human organic anion transporters and organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther 300: 918-924.
Uchino H, Tamai I, Yamashita K, Minemoto Y, Sai Y, Yabuuchi H, Miyamoto KI, Takeda E, and Tsuji A (2000) p-Aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 270: 254-259.[CrossRef][Medline]
Uwai Y, Saito H, Hashimoto Y, and Inui KI (2000) Interaction and transport of thiazide diuretics, loop diuretics and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther 295: 261-265.
van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG (2002) The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13: 595-603.
Zhang L, Schaner ME, and Giacomini KM (1998) Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 286: 354-361.
Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, and Giacomini KM (2000) Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos 28: 329-334.
This article has been cited by other articles:
![]() |
E. V. Wertheimer, A. M. Salicioni, W. Liu, C. L. Trevino, J. Chavez, E. O. Hernandez-Gonzalez, A. Darszon, and P. E. Visconti Chloride Is Essential for Capacitation and for the Capacitation-associated Increase in Tyrosine Phosphorylation J. Biol. Chem., December 19, 2008; 283(51): 35539 - 35550. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bahn, Y. Hagos, S. Reuter, D. Balen, H. Brzica, W. Krick, B. C. Burckhardt, I. Sabolic, and G. Burckhardt Identification of a New Urate and High Affinity Nicotinate Transporter, hOAT10 (SLC22A13) J. Biol. Chem., June 13, 2008; 283(24): 16332 - 16341. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vallon, T. Rieg, S. Y. Ahn, W. Wu, S. A. Eraly, and S. K. Nigam Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics Am J Physiol Renal Physiol, April 1, 2008; 294(4): F867 - F873. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hagos, A. Bahn, S. V. Vormfelde, J. Brockmoller, and G. Burckhardt Torasemide Transport by Organic Anion Transporters Contributes to Hyperuricemia J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3101 - 3109. [Full Text] [PDF] |
||||
![]() |
N. Mizuno, T. Takahashi, Y. Iwase, H. Kusuhara, T. Niwa, and Y. Sugiyama Human Organic Anion Transporters 1 (hOAT1/SLC22A6) and 3 (hOAT3/SLC22A8) Transport Edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) and Its Sulfate Conjugate Drug Metab. Dispos., August 1, 2007; 35(8): 1429 - 1434. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ueo, H. Motohashi, T. Katsura, and K.-i. Inui Cl--dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3 Am J Physiol Renal Physiol, July 1, 2007; 293(1): F391 - F397. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nozaki, H. Kusuhara, T. Kondo, M. Hasegawa, Y. Shiroyanagi, H. Nakazawa, T. Okano, and Y. Sugiyama Characterization of the Uptake of Organic Anion Transporter (OAT) 1 and OAT3 Substrates by Human Kidney Slices J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 362 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hagos, D. Stein, B. Ugele, G. Burckhardt, and A. Bahn Human Renal Organic Anion Transporter 4 Operates as an Asymmetric Urate Transporter J. Am. Soc. Nephrol., February 1, 2007; 18(2): 430 - 439. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hasegawa, H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi, and Y. Sugiyama Multidrug Resistance-Associated Protein 4 Is Involved in the Urinary Excretion of Hydrochlorothiazide and Furosemide J. Am. Soc. Nephrol., January 1, 2007; 18(1): 37 - 45. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Murakami, N. Kohyama, Y. Kobayashi, M. Ohbayashi, H. Ohtani, Y. Sawada, and T. Yamamoto FUNCTIONAL CHARACTERIZATION OF HUMAN MONOCARBOXYLATE TRANSPORTER 6 (SLC16A5) Drug Metab. Dispos., December 1, 2005; 33(12): 1845 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tahara, H. Kusuhara, H. Endou, H. Koepsell, T. Imaoka, E. Fuse, and Y. Sugiyama A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 337 - 345. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D Hughes How do thiazide and thiazide-like diuretics lower blood pressure? Journal of Renin-Angiotensin-Aldosterone System, December 1, 2004; 5(4): 155 - 160. [Abstract] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||